Feb 23, 2018 - Dynavax’s commercialization efforts with HEPLISAV-B get a boost.GW Pharmaceuticals’ GWP42006 fails in proof-of-concept study.Sangamo inks a deal with Gilead’s Kite Pharma unit.
Feb 22, 2018 - Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.
Feb 21, 2018 - Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q4 2017 Earnings Conference Call February 21, 2018, 16:30 ET Executives Todd Pettingill - IR John Higgins - CEO and Executive Director Matthew Foehr - Presid
Feb 19, 2018 - Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
Jan 30, 2018 - LGND is not a diversified biopharma technology specialist, but a one product commodity middleman.A direct Captisol substitute is available from a fully integrated, high-quality supplier.Ligand does no
Jan 28, 2018 - Tables of the top insider purchases and sales filed with the SEC on 1/26/18, based on dollar value. Dollar values often do not equate with significance when it comes to insider trades. Proprietary Ins
Jan 24, 2018 - Progenics has made a solid start to the year. Nymox announced positive long-term data on lead drug fexapotide. Ligand out-licensed OmniAb antibody discovery platform to Ferring Pharmaceuticals.
Jan 13, 2018 - With the TLANDO setback, the outlook for Lipocine is gloomy.Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib.Concert had a mixed day with t
Jan 12, 2018 - Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.
Jan 08, 2018 - Thyroid receptor agonists have long been known to substantially lower cholesterol.However, because of unintended consequences of raising thyroid hormones elsewhere in the body, they have, again and ag